Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer

2009; Elsevier BV; Volume: 56; Issue: 2 Linguagem: Inglês

10.1016/j.eururo.2009.03.073

ISSN

1873-7560

Autores

Michael J. Morris, Daisy Huang, William Kevin Kelly, Susan F. Slovin, Ryan D. Stephenson, C. Eicher, A. Delacruz, Tracy Curley, Lawrence H. Schwartz, Howard I. Scher,

Tópico(s)

Radiopharmaceutical Chemistry and Applications

Resumo

Growth of selected castration-resistant prostate cancer (CRPC) cell lines and animal models can be repressed by reexposure to androgens. Low doses of androgens, however, can stimulate tumor growth.

Referência(s)